Compare TMDE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMDE | HOTH |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.0M |
| IPO Year | 2025 | 2019 |
| Metric | TMDE | HOTH |
|---|---|---|
| Price | $0.74 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 23.1K | ★ 242.7K |
| Earning Date | 09-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $607,422,733.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.66 |
| 52 Week High | $6.27 | $3.80 |
| Indicator | TMDE | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.43 |
| Support Level | N/A | $1.13 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 73.08 |
TMD Energy Ltd is engaged in marine fuel bunkering services specializing in the supply and marketing of marine gas oil and marine fuel oil (including high sulfur fuel oil, low sulfur fuel oil and very low sulfur fuel oil), to ships and vessels at sea. It is also involved in the provision of ship management services for in-house and external vessels, as well as vessel chartering. It is currently operating with a fleet of nearly 15 bunkering vessels ranging from 540 dwt to 7,820 dwt, of which nearly nine (9) are double bottom and double hull vessels with an average cargo-carrying capacity of approximately 4,200 dwt each.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).